Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Babak Boroojerdi

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
BMC Neurology|August 12, 2011
Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson diseaseHan-Joon Kim, Beom S Jeon, Won Yong Lee, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 14, 2022
Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG-Associated Experimental Autoimmune EncephalomyelitisJana Remlinger, Adrian Madarasz, Kirsten Guse, et al.
Parkinsonism & Related Disorders|January 13, 2019
Clinical feasibility of a wearable, conformable sensor patch to monitor motor symptoms in Parkinson's diseaseBabak Boroojerdi, Roozbeh Ghaffari, Nikhil Mahadevan, et al.
Neurology and Therapy|July 1, 2022
Patient Experience in Early-Stage Parkinson's Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome AssessmentThomas Morel, Sophie Cleanthous, John Andrejack, et al.
Therapeutic Advances in Neurological Disorders|July 7, 2025
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label studyMiriam Freimer, Urvi Desai, Raghav Govindarajan, et al.
Journal of Patient-Reported Outcomes|April 20, 2023
Development and early qualitative evidence of two novel patient-reported outcome instruments to assess daily functioning in people with early-stage Parkinson'sThomas Morel, Sophie Cleanthous, John Andrejack, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 16, 2011
Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER)Claudia Trenkwalder, Bryan Kies, Monika Rudzinska, et al.
Plos One|December 21, 2017
Feasibility of large-scale deployment of multiple wearable sensors in Parkinson's diseaseAna Lígia Silva de Lima, Tim Hahn, Luc J W Evers, et al.
The Lancet. Rheumatology|March 16, 2023
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trialAndrew L Mammen, Anthony A Amato, Mazen M Dimachkie, et al.
Clinical Pharmacology and Therapeutics|September 24, 2019
Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial DesignsMalidi Ahamadi, Daniela J Conrado, Sreeraj Macha, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
BMC Neurology|August 12, 2011
Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson diseaseHan-Joon Kim, Beom S Jeon, Won Yong Lee, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 14, 2022
Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG-Associated Experimental Autoimmune EncephalomyelitisJana Remlinger, Adrian Madarasz, Kirsten Guse, et al.
Parkinsonism & Related Disorders|January 13, 2019
Clinical feasibility of a wearable, conformable sensor patch to monitor motor symptoms in Parkinson's diseaseBabak Boroojerdi, Roozbeh Ghaffari, Nikhil Mahadevan, et al.
Neurology and Therapy|July 1, 2022
Patient Experience in Early-Stage Parkinson's Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome AssessmentThomas Morel, Sophie Cleanthous, John Andrejack, et al.
Therapeutic Advances in Neurological Disorders|July 7, 2025
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label studyMiriam Freimer, Urvi Desai, Raghav Govindarajan, et al.
Journal of Patient-Reported Outcomes|April 20, 2023
Development and early qualitative evidence of two novel patient-reported outcome instruments to assess daily functioning in people with early-stage Parkinson'sThomas Morel, Sophie Cleanthous, John Andrejack, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 16, 2011
Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER)Claudia Trenkwalder, Bryan Kies, Monika Rudzinska, et al.
Plos One|December 21, 2017
Feasibility of large-scale deployment of multiple wearable sensors in Parkinson's diseaseAna Lígia Silva de Lima, Tim Hahn, Luc J W Evers, et al.
The Lancet. Rheumatology|March 16, 2023
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trialAndrew L Mammen, Anthony A Amato, Mazen M Dimachkie, et al.
Clinical Pharmacology and Therapeutics|September 24, 2019
Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial DesignsMalidi Ahamadi, Daniela J Conrado, Sreeraj Macha, et al.
Pageof 7